Program
Anti-B7-H3 Antibody-drug Conjugate MHB088C
Its studies are mostly in Small Cell Lung Carcinoma, led by 2 companies.
Drug pageAnti-B7-H3 Antibody-drug Conjugate MHB088C: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Minghui Pharmaceuticalits history only | 22 open or running | phase 2since Nov 30, 2022 | Nov 30, 2022 | Aug 2029phase 2 · NCT07126665 |
| Qilu Pharmaceuticalits history only | 22 open or running | phase 3since Apr 18, 2025 | Apr 18, 2025 | May 2027phase 3 · NCT06954246 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 30, 2022First study: phase 2 study in Advanced or Metastatic Solid TumorsNew to Minghui PharmaceuticalMinghui Pharmaceutical · NCT05652855 · 48 planned · Australia
- Apr 18, 2025Qilu Pharmaceutical’s first study: phase 3 study in Small Cell Lung CarcinomaNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT06954246 · 450 planned · China
- Jul 28, 2025Phase 2 study in Advanced/Metastatic Solid TumorsQilu Pharmaceutical · NCT07102004 · 515 planned · China
- Aug 11, 2025Phase 2 study in Advanced Malignant Solid TumorMinghui Pharmaceutical · NCT07126665 · 116 planned · China
Ahead
- May 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaQilu Pharmaceutical · NCT06954246
- Aug 2029Primary completion: phase 2 study in Advanced Malignant Solid TumorMinghui Pharmaceutical · NCT07126665
TargetBeta
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) ”NCIt, by rule
Other programs on CD276
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risvutatug rezetecan | Hansoh Pharmaceutical Group | phase 3 | 30 |
| ifinatamab deruxtecan | Merck | phase 3 | 16 |
| tambotatug pelitecan | MediLink Therapeutics (Suzhou) | phase 3 | 13 |
| Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 | CSPC Pharmaceutical Group | phase 3 | 5 |
| Elfetabart Drozuntecanrule | BioNTech | phase 3 | 3 |
| Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101rule | tj-biopharma-co-ltd | phase 3 | 3 |
| Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01rule | radiopharm-theranostics-ltd | phase 2 | 1 |
| Autologous Anti-B7-H3 CAR T-cells BCB-276rule | brainchild-bio-inc | phase 2 | 1 |
| Anti-B7-H3/CD28 Bispecific Antibody XmAb808rule | Xencor | phase 1 | 2 |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | ideaya-biosciences | phase 1 | 1 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
| HLX316 | Fosun Pharma | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07126665Advanced Malignant Solid Tumor · China | 2 | Recruiting | Minghui Pharmaceutical | Aug 2029 | 116 |
| NCT07102004Advanced/Metastatic Solid Tumors · China | 2 | Recruiting | Qilu Pharmaceutical | Jul 2026 | 515 |
| NCT06954246Small Cell Lung Carcinoma · China | 3 | Recruiting | Qilu Pharmaceutical | May 2027 | 450 |
| NCT05652855Advanced or Metastatic Solid Tumors · Australia | 2 | Not yet recruiting | Minghui Pharmaceutical | Jan 31, 2026 | 48 |
How it is read
Names in the registry
- “MHB088C for Injection”, 4 entries
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.